Treatment of ophthalmic conditions
    1.
    发明申请
    Treatment of ophthalmic conditions 审中-公开
    眼科治疗

    公开(公告)号:US20050245497A1

    公开(公告)日:2005-11-03

    申请号:US11102586

    申请日:2005-04-08

    IPC分类号: A61K31/56 A61K31/573

    CPC分类号: A61K31/56 A61K31/573

    摘要: The present invention provides a method of treatment of an individual with an ophthalmic condition that may comprise the step of: administering to the individual a therapeutically effective amount of a compound capable of modulating the activity of mineralocorticoid receptors within cells or tissue located in an eye or adjacent to an eye in the individual to be treated. Preferably, said compound may be an anti-oedematous steroid, more preferably a mineralocorticoid.

    摘要翻译: 本发明提供一种用眼科病症治疗个体的方法,该方法可以包括以下步骤:向个体施用治疗有效量的能够调节位于眼睛内的细胞或组织内的盐皮质激素受体活性的化合物,或 相邻于待治疗的个体的眼睛。 优选地,所述化合物可以是抗水性类固醇,更优选盐皮质激素。

    Laser coagulation of an eye structure from a remote location
    2.
    发明授权
    Laser coagulation of an eye structure from a remote location 有权
    从远程位置激光凝结眼结构

    公开(公告)号:US08903468B2

    公开(公告)日:2014-12-02

    申请号:US13573100

    申请日:2012-08-20

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    IPC分类号: A61B5/05 A61F9/008

    摘要: An integral laser imaging and coagulation apparatus, and associated systems and methods that allow an ophthalmologist to perform laser retinal surgical procedures with an integral laser imaging and coagulation apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. In some embodiments, communication between the integral laser imaging and coagulation apparatus and control system is achieved via the Internet®.

    摘要翻译: 整体激光成像和凝固装置以及相关的系统和方法,其允许眼科医生执行激光视网膜外科手术,其中整体式激光成像和凝固装置设置在设置在第二(即, 远程)位置,例如医生办公室。 在一些实施例中,整体激光成像和凝固装置与控制系统之间的通信通过因特网进行。

    Method and system for three-dimensional (3D) imaging of biological structures
    3.
    发明授权
    Method and system for three-dimensional (3D) imaging of biological structures 有权
    生物结构三维(3D)成像的方法和系统

    公开(公告)号:US08517944B2

    公开(公告)日:2013-08-27

    申请号:US13066012

    申请日:2011-04-04

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    IPC分类号: A61B8/00

    摘要: An ultrasonic scanning apparatus that includes a unique ultrasonic array to transmit ultrasonic energy to a biological structure, such as an eye. The ultrasonic array provides specific three-dimensional (3-D) information relating to the eye and precise volumetric information relating to structures associated therewith, such as a tumor, prior, during and/or after treatment. The ultrasonic array can also be combined with a therapeutic ultrasonic unit for real-time 3-D observation of a structure and the focal point of the transmitted therapeutic beam(s) on a monitor during the treatment of a structure, e.g., treatment of a lesion.

    摘要翻译: 一种超声波扫描装置,其包括用于将超声波能量传输到诸如眼睛的生物结构的唯一超声波阵列。 超声波阵列提供与眼睛相关的特定三维(3-D)信息和与其相关的结构如肿瘤,治疗前,治疗期间和/或之后有关的精确体积信息。 超声波阵列还可以与治疗性超声波单元组合,用于在结构治疗期间对监测器上的结构和透射治疗束的焦点进行实时3-D观察,例如治疗 病变。

    Intravitreal injection device and system
    4.
    发明申请
    Intravitreal injection device and system 有权
    玻璃体内注射装置和系统

    公开(公告)号:US20100100054A1

    公开(公告)日:2010-04-22

    申请号:US12456439

    申请日:2009-06-16

    IPC分类号: A61M5/32

    摘要: An intravitreal injection system for administering a pharmacological agent formulation to an intravitreal compartment of an eye, comprising (i) an injection member coupled to, or comprising, an internal formulation chamber that is adapted to receive and contain the pharmacological agent formulation therein, (ii) a needle having a first end that is in communication with a formulation chamber and a second injection end, and (iii) a movable platform for positioning the system on the eye, guiding the needle, and limiting the penetration depth of the needle into the eye.

    摘要翻译: 一种玻璃体内注射系统,用于向眼睛的玻璃体腔内施用药物制剂,其包含(i)与适于在其中接受和容纳其药理学制剂的内部制剂室耦合或包含的注射构件(ii) )具有与制剂室和第二注射端连通的第一端的针,以及(iii)用于将系统定位在眼睛上的引导针,并且将针的穿入深度限制到 眼。

    Neural conduit agent dissemination
    5.
    发明申请
    Neural conduit agent dissemination 审中-公开
    神经导管剂传播

    公开(公告)号:US20070237722A1

    公开(公告)日:2007-10-11

    申请号:US11277639

    申请日:2006-03-28

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    摘要: A method for agent dissemination using a neural conduit. In one embodiment, agent dissemination is facilitated, for example, by the application of thermal energy, ultrasound energy, radiant energy, electromagnetic energy, or electrical current. As one example, agent may be provided to a sensory organ such as the eye for dissemination along the optic nerve to the central nervous system. As another example, agent may be provided at an acupuncture site for dissemination along a peripheral nerve to either a second peripheral nerve site or a central nervous system site.

    摘要翻译: 一种使用神经导管进行药剂传播的方法。 在一个实施方案中,例如通过应用热能,超声能量,辐射能,电磁能或电流来促进药剂传播。 作为一个示例,可以向诸如眼睛的感觉器官提供药剂以沿着视神经传播到中枢神经系统。 作为另一示例,可以在针灸部位处提供试剂以沿周围神经传播到第二周围神经部位或中枢神经系统部位。

    Ocular solutions
    7.
    发明申请
    Ocular solutions 审中-公开
    眼科解决方案

    公开(公告)号:US20060228394A1

    公开(公告)日:2006-10-12

    申请号:US11451100

    申请日:2006-06-12

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    摘要: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.

    摘要翻译: 含有至少一种大环内酯类抗生素和/或霉酚酸的眼溶液提供抗炎,抗细胞增殖,抗细胞迁移,抗血管生成,抗微生物和抗真菌作用。 在一个实施方案中,在插入置换的眼内晶状体之前,在白内障手术后眼内施用溶液,导致后囊膜混浊减少,这可能消除对后续手术的需要。 溶液可以是侵入性给药的溶液,例如含有至少一种大环内酯类抗生素如他克莫司,西罗莫司,依维莫司,环孢菌素和子囊霉素或霉酚酸的灌洗或体积替代溶液。 溶液可以是以滴剂,软膏剂,凝胶剂,霜剂等形式非侵入性或局部施用的溶液,并且可以包括眼睛润滑剂和隐形眼镜溶液。 溶液可以含有治疗剂浓度高的药剂,使得局部给药溶液的治疗浓度积聚在足以治疗疾病的患病眼部结构中。 药剂可以用聚合物或其它组分配制用于延长或缓释,以在治疗过程中提供基本恒定的浓度。

    Drug delivery system and method
    8.
    发明申请
    Drug delivery system and method 审中-公开
    药物输送系统及方法

    公开(公告)号:US20060216329A1

    公开(公告)日:2006-09-28

    申请号:US11442580

    申请日:2006-05-26

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    IPC分类号: A61F2/16

    摘要: A method of introducing a beneficial substance into the body is presented. The method includes the steps of loading biodendrimer with the beneficial substance, and positioning the biodendrimer relative to the body, such that the beneficial substance can be absorbed by the body.

    摘要翻译: 提出了一种将有益物质引入体内的方法。 该方法包括将生物聚合物与有益物质一起加载并相对于身体定位生物聚合物的步骤,使得有益物质可以被身体吸收。

    Ocular solutions
    9.
    发明授权
    Ocular solutions 有权
    眼科解决方案

    公开(公告)号:US07087237B2

    公开(公告)日:2006-08-08

    申请号:US10667161

    申请日:2003-09-19

    申请人: Gholam Peyman

    发明人: Gholam Peyman

    IPC分类号: A61K9/00 A61F13/00 A61F2/00

    摘要: Containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

    摘要翻译: 含有至少一种大环内酯类抗生素和/或霉酚酸提供抗炎,抗细胞增殖,抗细胞迁移,抗血管生成,抗微生物和抗真菌作用。 在一个实施方案中,在插入置换的眼内晶状体之前,在白内障手术后眼内施用溶液,导致后囊膜混浊减少,这可能消除对后续手术的需要。 溶液可以是侵入性给药的溶液,例如含有至少一种大环内酯类抗生素如他克莫司,西罗莫司,依维莫司,环孢菌素和子囊霉素或霉酚酸的灌洗或体积替代溶液。 溶液可以是以滴剂,软膏剂,凝胶剂,霜剂等形式非侵入性或局部施用的溶液,并且可以包括眼睛润滑剂和隐形眼镜溶液。